1 Supplementary materials to Papp et al. "Rucaparib blocks SARS-CoV-2 virus binding to 2 cells and interleukin-6 release in a model of COVID-19"

3

4 Supplementary methods

5 Chemicals

Rucaparib was a generous gift from Dr. Thomas Harding (Clovis Oncology, Boulder, CO,
USA), while Talazoparib and Olaparib was purchased from Sigma (St. Louis, MO, USA) and
Stenoparib was from Selleckchem (Houston, TX, USA). LPS was from Sigma (St. Louis, MO,
USA Cat. No: L4516), while the spike protein used to induce macrophages was from Merck
(Kenilworth, NJ, USA, Cat. No.:AGX818).

11

12 COVID-19 Patients

Formalin-fixed, paraffin embedded (FFPE) blocks of patients was assessed who died of
COVID-19 at Szent Erzsébet Hospital (Sátoraljaújhely, Hungary) between 30th November 2020
- 6th February 2021. Controls were patients died of non-COVID-19 causes. Controls were
selected from patients died in the same period of non-COVID-19 and not lung-related causes
at the clinical units of the University of Debrecen. Demographics of the patients are in
Supplementary Table 1. We excluded patients with nosocomial infections in their records.
The study was authorized by the local ethical board (6043/2022).

20

21 Blood donors

Monocytes were prepared from buffy coat of healthy donors. The study was authorized by the local ethical board (Reg. No. 938-2/2014/5200). Three-three donors were used in the LPS-

- 24 induction and spike-induction experiments.
- 25

26 Immunohistochemistry for poly(ADP-ribose), 4-hydroxynonenal (HNE) and spike protein

27 Five micron thick sections were obtained from formalin-fixed, paraffin embedded blocks of

- 28 COVID-19 patients. Immunohistochemistry was performed as in^{1,2} with the conditions in
- 29 Supplementary Table 2.
- 30
- 31 Cell culture

Vero E6 cells were cultured at 37 °C, 5% CO₂ in DMEM supplemented with 10% FBS and 1%
penicillin-streptomycin.

Human embryonic kidney cells (HEK-293T) cells expressing ACE2 receptor and the TMPRSS2 protease (GeneCopoeia, Rockville, MD, USA) were grown in DMEM supplemented with 10 % FBS, and selection antibiotics (hygromycin 100 µg/mL, puromycin 1 µg/mL) and

37 maintained in 37 C, 5% CO2 incubator.

A549 lung adenocarcinoma constitutively expressing FLAG-tagged SARS-CoV-2 Nsp3
macrodomain or its control empty vector³ were grown in DMEM/high glucose media (Thermo)
supplemented with 10% Fetal Bovine Serum (Thermo) and maintained at 37°C in a humidified
atmosphere containing 5% CO₂.

- 42
- 43 Viruses

SARS-CoV-2 B.1.5 (Accession ID: EPI_ISL_483637, with D614G mutation), B.1.1.7.
(Accession ID: EPI_ISL_826270) and B.1.617.2 (Accession ID: EPI_ISL_9625925) variants
were isolated at the National Laboratory of Virology (University of Pécs, Pécs, Hungary).
Variants were verified by sequencing.

48 SARS-CoV-2 spike protein-pseudotyped lentivirions were produced by transfection of HEK-49 293T cells with the following plasmids: pLenti CMV GFP Puro expression vector, psPAX2 50 packaging plasmid (Addgene, Watertown, MA, USA), and pcDNA3.1 plasmids coding for either 51 the Wuhan-Hu-1 prototypical, the 1.617 or the 1.351 SARS-CoV-2 spike variant (GenScript 52 Biotech, Piscataway NJ, USA). Transfection was done in a 1:1:1 ratio using the 53 polyethylenimine (PEI) method, and virion production was carried out as described previously ⁴. Following collection and concentration of the pseudovirions, an enzyme-linked 54 55 immunosorbent assay (ELISA)-based colorimetric reverse transcriptase (RT) assay (Roche 56 Applied Science, Mannheim, Germany) was then used to detect the amount of RT in the virus 57 samples, and transduction (infection) of cells was carried out using 4 ng RT-equivalent of the 58 pseudovirions (MOI 0.2).

59

60 Virus proliferation assay

61 In a 96-well cell culture plate, 3x 10⁵ Vero E6 cells were seeded on the previous day of the 62 infection. Treatment with the different PARP inhibitors (eucaparib, olaparib, talazoparib) from 63 $40 - 2.5 \mu$ M were done at the same time with the infection of SARS-CoV-2 (Accession ID: 64 EPI ISL 483637, B.1.5 variant) at MOI 0.01 in a BSL-4 laboratory. After a 30 minutes of incubation in a cell culture CO₂ incubator, the mixture of the virus and the compound was 65 replaced with only compound containing cell culture media (DMEM, 2% HI FBS, 1% PS), 48 66 67 hours post infection the supernatant was collected. RNA extraction was performed using the 68 Monarch Total RNA miniprep kit (New England Biolabs, Ipswitch, MD, USA). Viral titer from 69 the supernatant was determined using a QX200 AdutoDG Droplet- Digital PCR using the 70 ddPCR Supermix (both from Bio-Rad, Hercules, CA, USA). The PCR was specific for the 71 SARS-CoV-2 RdRp gene (forward primer: GTGARATGGTCATGTGTGGCGG; reverse: 72 CARATGTTAAASACACTATTAGCATA, probe FAM-CAGGTGGAACCTCATCAGGAGATGC-73 BBQ). IC_{50} was determined by performing a non-liner regression using the [Inhibitor] vs.

- response variable slope (four parameters) macro of Graphpad Prism. For rucaparib the R2 value was $R^{2}_{infection}=0.8176$.
- 76
- 77 Viability assays

Cell viability was assessed in Vero E6 cells using the CellTiter-Glo assay (Promega, Madison,
 WI, USA). IC₅₀ was determined by performing a non-liner regression using the [Inhibitor] vs.

- 80 response variable slope (four parameters) macro of Graphpad Prism. The R² value for the
- 81 goodness of fit was R²_{viability}=0.9776 for Rucaparib.
- 82

83 Neutralization assay on Vero E6 cells

84 8 x 10⁵ Vero E6 cells were seeded in a 48-well plate. The next day the plate was transferred 85 to the BSL-4 laboratory. SARS-CoV-2 B.1.1.7 viral stocks were diluted to 0.01 MOI in DMEM 86 (Lonza, Basel, Switzerland). Virus suspension (25 µl) was mixed with 25 µl rucaparib (60, 44 87 and 10 µM diluted in DMEM) and incubated for an hour at room temperature. After the 88 incubation period 450 µI DMEM was added to the mixture then it was added to the cells. The cells were infected for 30 min at 37 °C. The SARS-CoV-2 and rucaparib mixture was then 89 90 discarded and the cells were incubated for 2 days with DMEM supplemented with 2% HI FBS 91 and 1% Pen-Strep. 48 hours post infection the supernatant was collected. RNA extraction was 92 performed using the EXM 3000 nucleic acid isolation system (Zybio, Chongqing, China). Viral 93 titer from the supernatant was determined using a QX200 AdutoDG Droplet- Digital PCR using 94 the ddPCR Supermix (both from Bio-Rad, Hercules, CA, USA). The PCR was specific for the 95 SARS-CoV-2 RdRp gene (forward primer: GTGARATGGTCATGTGTGGCGG; reverse: 96 CARATGTTAAASACACTATTAGCATA, probe FAM-CAGGTGGAACCTCATCAGGAGATGC-97 BBQ).

98

99 Neutralization assay on hybrid HEK293T cells

100 The day before the experiment, HEK-293T cells expressing ACE2 receptor and the TMPRSS2 101 protease (GeneCopoeia, Rockville, MD, USA) were passaged into 48-well plate (30 000 102 cells/well) in DMEM containing 10 % FBS and 1 % penicillin-streptomycin. On the next day, 35 103 µM of rucaparib in DMSO was incubated with 4 ng/ul RT-equivalent of the pseudovirions for 104 30 minutes in DMEM medium without serum or antibiotics (50 µl total), in 37 C. For controls, 105 equivalent amount of DMSO was added to the pseudovirions in the absence of rucaparib. The 106 media on the cells were then removed, and the virus-inhibitor medium was complemented with 107 450 µI DMEM containing 10 % FBS, 1 % penicillin-streptomycin, and thereafter added to the 108 wells (48-well plate). The cells were then incubated for 48 hours in 37 C, after which the media 109 was removed from the wells, and the cells were collected in PBS (400 µl) for analysis of GFP 110 fluorescence indicating transduction using flow cytometry (FACSCalibur, BD Bioscience,

Franklin Lakes NJ, USA), counting 3000 cells/sample. Measurement was carried out in
triplicates. Cells were visually inspected for signs of cell death and signs of cell death was not
observed in any of the experiments reported.

114

115 Monocyte differentiation

116 Peripheral blood mononuclear cells (PBMC) were isolated from three different buffy coat 117 samples received from the Hungarian National Blood Transfusion Service. To separate 118 mononuclear cells, we layered the diluted blood sample in 1:1 ratio with basal RPMI 1640 119 Medium (Lonza, Cat. No: 12-167F) onto the Lymphocyte Separation Medium 1077 120 (PromoCell, Cat. No: CC-44010.) and applied a centrifugation step (400 g, for 30 min, at room 121 temperature with4/1 acceleration/deceleration). The layer of the mononuclear cells was 122 transferred, washed with PBS (Lonza, Belgium, Cat. No: 17-516F) and centrifuged at 300 g 123 for 10 min at room temperature. Following cell counting 5x10⁵ cells per well were seeded to 124 24-well plates (Greiner, Germany, Cat. No: 662160) in complete RPMI 1640 Medium 125 supplemented with Fetal Bovine Serum (Biosera, USA, MO, Cat. No: FB-1350-500) Penicillin-126 Streptomycin (Lonza, Belgium, Cat. No: DE17-602E) and L-glutamine (Lonza, Belgium, BE-127 17-605E). To induce macrophage differentiation, we incubated the cells for 5 days at 37 °C, 128 5% CO_2 in a humidified atmosphere.

129

130 Treatment of differentiated macrophages

131 In the first part of the experiment, differentiated macrophages were treated in three parallels 132 with the combination of 100 ng/ml LPS (Sigma, USA, MA, Cat. No: L4516) and three different 133 PARP inhibitor molecules diluted in DMSO (Santa Cruz, USA, CA, Cat. No: sc-358801). A 24-134 hour treatment was applied using 20 µM concentration of Rucaparib and Olaparib and 10 µM 135 concentration of Talazoparib. In all cases 0.1 % DMSO concentration was used as solvent 136 control. The positive control was treated with 0.1 µM and 1 µM Dexamethasone (Teva, 137 Hungary, Cat. No: OGYI-T-6071/03). Following incubation supernatants were collected for 138 further investigation. Monocytes from three donors were accessed and were plotted. The 139 vehicle was 0.01% DMSO.

In the second part of the experiment, three parallels of differentiated macrophage cells (three different donors, 30 000 cells/well) were pretreated for 48 hours with 20 nM spike protein (Merck, Germany, Cat. No: AGX818). Rucaparib was added after 48 hours in 5 different concentrations (500 nM, 1 μ M, 5 μ M, 15 μ M, 27 μ M) and incubated for 24 hours. The positive control was treated with 1 μ M Dexamethasone (Teva, Hungary, Cat. No: OGYI-T-6071/03). Supernatants and cell pellets were collected for further assays. One representative donor is displayed in three biological replicates due to a large heterogeneity of the donor responses.

148 Inflammatory cytokine concentration measurement using Luminex xMAP technology

149 Luminex performed Multiplex Immunoassay was to determine the following 150 cytokines/chemokine concentrations using customized Milliplex Human 151 Cytokine/Chemokine/Growth Factor Panel A Magnetic Bead Panel (Cat. Nr. HCYTA-60K, 152 Merck Millipore, Darmstadt, Germany): interleukin-10 (IL-10); IL-1β; IL-2; IL-6; IL-8; tumor 153 necrosis factor-alpha (TNF- α). Following previous optimizations, the undiluted samples were 154 tested in a blind-fashion and in duplicate. The experiment was performed according to the 155 instructions of the manufacturer. Briefly, 25 µl volume of each sample, control, and the 156 standard was added to a 96-well plate (provided by the kit) containing 25 µl of fluorescent-157 coded, capture antibody-coated beads. After the appropriate washing and incubation periods, 158 biotinylated detection antibodies and streptavidin-PE were added to the plate. 150 µl volume 159 of drive fluid was added to the wells after the last washing step, and the plate was incubated 160 and read on the Luminex MagPix instrument. Five-PL regression curves were used to plot the 161 standard curves for the analytes by the Belysa 1.1 (Merck KGaA, Darmstadt, Germany) 162 software analyzing the bead median fluorescence intensity. Results are shown in pg/mg.

163

164 Inflammatory cytokine concentration measurement using the Proquantum kit series

165 In spike induction experiments IL-6 (A35575), TNF α (A35601) and IL-1 β (A35574) were 166 determined using the respective Proquantum assay kits (ThermoFisher, Waltham, MA, USA) 167 according to the instructions of the manufacturer.

168

169 Western blotting

170 Western blots were performed as previously described³. Briefly, cells were lysed directly in 171 pre-heated Laemmli buffer, quantified (BCA protein quantification kit - Pierce, Appleton WI, 172 USA), loaded (20 µg) in standard 10% SDS-PAGE gels and transferred to nitrocellulose 173 membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% skim milk for 174 30 min and incubated with primary antibodies (anti-p.STAT1 - 1:1000, Cell Signaling #9167; 175 anti-FLAG - 1:1000, Sigma #F1804; anti-tubulin - 1:5000, Abcam #Ab18251) (Cell Signaling, 176 Danves, MA, USA; Abcam, Cambridge, UK) diluted in 5% BSA in TBST buffer, overnight at 177 4°C. Membranes were extensively washed, incubated in appropriate HRP-conjugated 178 secondary antibodies (Sigma), washed, incubated with ECL Prime (Amersham, Amersham, 179 UK) and the signal was detected using a Chemidoc MP Imaging System (Bio-Rad, Hercules, 180 CA, USA). Signals were quantified using ImageJ software.

181

182 Immunofluorescence staining for ADP-ribose and FLAG

As previously described³, A549 cells, either transduced with empty vector control or lentiviral
 constructs for FLAG-tagged SARS-CoV-2 macrodomain overexpression were seeded in

185 microscopy-compatible plastic 96-well plates at the density of 10⁴ cells/well (Corning, Corning, 186 NY, USA), treated as required, washed with PBS and fixed with 4% EM-grade PFA (EMS, 187 Dormat, Switzerland), which was subsequently quenched twice with 0.1 M glycine and washed 188 in PBS. After permeabilization in 0.2% TritonX-100 in PBS, samples were blocked in 10% FBS 189 in permeabilization solution and incubated with primary antibodies (anti-ADP-ribose - 1:500, 190 Millipore #MABE1016; anti-FLAG - 1:500, Sigma #F1804) (Millipore, Burlington MA, USA) for 191 1h at room temperature in blocking solution. Samples were extensively washed in PBS, 192 incubated with appropriate fluorescently labelled secondary antibodies (Thermo), stained with 193 DAPI (Thermo), washed and maintained in 30% glycerol. For Western blot the seeding density 194 was 2x10⁵ cells/well.

Fluorescence microscopy images were acquired on a customized TissueFAXS i-Fluo system
(TissueGnostics, Wien, Austria) mounted on a Zeiss AxioObserver 7 microscope (Zeiss,
Oberkochen, Germany), using 20x Plan-Neofluar (NA 0.5) objective and an ORCA Flash 4.0
v3 camera (Hamamatsu, Hamamatsu city, Japan). Acquired images were analyzed using
StrataQuest software (TissueGnostics, Wien, Austria).

- PAR immunofluorescence experiments were repeats were 8, for STAT1 phosphorylation or
 FLAG immunoblotting repeats were 4. All values were normalized to the IFNγ-treated empty
 vector control.
- 203

204 SARS-CoV-2 spike protein binding assay

205 Assessment of SARS-CoV2 RBD and hACE2 binding inhibition was performed using RayBio® 206 kit (CoV-SACE2-1, COVID-19 spike-ACE2 binding assay RayBiotech Inc., 207 https://www.raybiotech.com/covid-19-spike-ace2-binding-assay-kit-en/?variation id=107121). 208 Recombinant SARS-CoV-2 spike RBD protein coated wells were treated with the compounds 209 (rucaparib, stenoparib, olaparib) in the range of concentration from 1 μ M up to 500 μ M, then 210 incubated for 16 h at 4 °C. Next, the recombinant hACE2 protein was added and the protocol 211 provided by the manufacturer was followed. In brief: unbound hACE2 protein was removed by 212 washing, and binding was assessed based on HRP-conjugated IgG in the presence of 213 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The HRP-conjugated IgG binds to the hACE2 214 protein and reacts with the TMB solution, producing a blue color that is proportional to the 215 amount of bound hACE2. The HRP-TMB reaction is halted with the addition of the Stop 216 Solution, resulting in a blue-to-yellow color change. The intensity of the yellow color is then 217 measured by absorbance at 450 nm with a microplate reader SpectraMax® iD5 (Molecular 218 Devices, LLC., San Jose, CA, USA). Data points were obtained as average of duplicates and 219 IC₅₀-curves were fitted by non-linear regression using GraphPad Prism.

220

221 Molecular modeling

222 We have used the FTMap protein mapping algorithm to identify possible binding sites on the 223 protein-protein interaction surface of the spike protein receptor-binding domain (RBD) vs. the 224 human ACE2 receptor^{5,6}. Briefly, the FTMap method distributes small organic probe molecules 225 on a dense grid defined on the protein surface, finds the most favorable positions for each 226 probe type, and identifies preferred binding hotspots as regions that bind multiple probe 227 clusters. Here, we have used the experimentally determined structures of the ACE2-RBD 228 complex for the B.1.5 ("Wuhan", PDB ID: 6M0J)⁷, B.1.617.2 ("Delta", PDB ID: 7WBQ) and 229 B.1.1.529 ("Omicron", PDB ID: 7WBP) variants⁸, and observed exactly one binding hotspot at 230 the protein-protein interaction surface of all three variants, characterized by the residues 493-231 498, with further sidechains R403, E406, Y449, Y453, N501 and Y505 in the vicinity. After 232 preparing the structure of rucaparib with LigPrep⁹, ligand docking was carried out with the 233 single precision (SP) mode of Glide ^{10,11}, and the binding mode was visualized with Maestro.

234

235 Sequence homology alignment

236 spike protein amino acid sequence was retrieved from https://viralzone.expasy.org/9556. 237 Sequences were retrieved for the wild type (https://www.uniprot.org/uniprot/P0DTC2), the 238 (https://www.ncbi.nlm.nih.gov/protein/QWE88920), alpha the beta 239 (https://www.ncbi.nlm.nih.gov/protein/QRN78347). the gamma 240 (https://www.ncbi.nlm.nih.gov/protein/QVE55289), the delta 241 (https://www.ncbi.nlm.nih.gov/protein/QWK65230), **BA.1** the omicron 242 (https://www.ncbi.nlm.nih.gov/protein/UFO69279.1?report=fasta), the omicron BA.2 243 (https://www.ncbi.nlm.nih.gov/protein/UJE45220.1?report=fasta), and the epsilon 244 (https://www.ncbi.nlm.nih.gov/protein/QQM19141) variants. The relevant parts of the 245 sequence were aligned using the ClustalW algorithm (https://www.genome.jp/tools-246 bin/clustalw). All sites were accessed the 1st April 2022.

- 247 On the figure conserved amino acids as compared to the wild type variant are in green. The 248 non-conserved amino acids are represented in red.
- 249

250 Expression and purification of the receptor binding domain of the spike protein

251 The receptor-binding domain (RBD) of the SARS-CoV-2 virus spike protein (³¹⁹Arg-⁵⁴¹Phe)

252 (Wuhan-Hu-1) was used in the experiments. Suspension HEK-293 cells stably expressing the

253 RBD secreted to the culture media were created by the Sleeping Beauty transposon method

using the p10-IRES2-eGFP vector construct as in a different application, described previously[31].

The RDB sequence, as produced by Amanat et al. [32], was inserted to the Sleeping Beauty transposon plasmid. The sequence on the N-terminal includes a signal peptide responsible for the secretion of the protein to the culture media and 6x His tag was introduced on the C- 259 terminal. Shaken cultures of suspension-adapted HEK293 cells were grown in a serum-free 260 FreeStyle 293 expression medium (Gibco, Waltham, MA, USA, Cat. no. 12338018) incubated 261 at 37°C and 5% CO2, shaken at 100 rpm. The cells were sub-cultured every 3-4 days with 262 seeding densities of 2 ×105 cells/mL to promote cell growth and scale-up. The RBD was 263 produced in a 300 mL shake flask cell culture. Cells were removed after 5-6 days by 264 centrifugation (20 min, 1000 rpm, Rotanta 460R, Hettich, Kirchlengern, Germany). The 265 purification of RBD was accomplished by immobilized nickel ion affinity chromatography. The 266 supernatant was loaded into a 5 mL HisTrap HP column (GE Healthcare, Chicago, IL, USA), 267 which was connected to an FPLC system (ÄKTA pureTM, GE Healthcare, Chicago, IL, USA). 268 Protein bound to the column was eluted by imidazole (200 mM, pH 7.4). The protein-containing 269 fraction was concentrated while the elution buffer was replaced by phosphate buffer (pH 6.8) 270 using a centrifugal filter device. Centrifugation (Rotanta 460R, Hettich, Kirchlengern, Germany) 271 was performed at 4000 g for 20 minutes using a 30 KDa MWCO filter (Vivacell 100, Sartorious, 272 Göttingen, Germany). The purity of the produced protein was confirmed by SDS-PAGE and 273 the protein concentration was determined by UV-Vis spectroscopy at 280 nm.

274

275 Nuclear Magnetic Resonance (NMR)-based investigation of spike-rucaparib interaction

276 Solution phase NMR experiments were performed under the following conditions.

The RBD of spike (~ 28 kDa) + rucaparib camsylate assay mixture contained 33 μ M RBD (in 540 μ L) and 1 mM rucaparib (dissolved in DMSO-d₆ in 20 μ L) + 10% D₂O for lock in sodiumphosphate buffer (0.2 M, pH 6.8). Rucaparib was in ~30 fold excess. The RBD and rucaparib were assessed also without the other partner under the same conditions as references.

281 Bruker Avance Neo 700 MHz spectrometer (Bruker, Billerica, MA, USA) equipped with a 282 Prodigy TCI cryoprobe was used. Experiments were run at 298K temperature and 10% D₂O 283 was added to the solution for stabilizing the magnetic field via the ²H lock channel. Typical 90 284 degree ¹H pulse duration was 11.5 µs. The residual DMSO-d₆ signal (2.59 ppm) was used as 285 ¹H chemical shift reference. The NMR verification of the structure of rucaparib-camphor 286 sulfonic acid (camsylate) salt was carried out in pure DMSO-d₆ solvent and yielded a full 287 assignment of all ¹H and ¹³C signals (spectra not shown). The assignments of aromatic (H15. 288 H16, H18, H19) and olefinic (H11, H13) protons could be easily transferred to the buffer, 289 containing rucaparib with or without the RBD protein. Excitation sculpting water suppression 290 ¹H-NMR spectra using manufacturers 'zgesfpgp' pulse sequence was applied (**FigS1G**)¹². The 291 drug ligand signal appear as sharp signals while the protein signals are weak and broad (due 292 to concentration and MW differences). A relatively strong and well separated RBD signal at 293 0.4 ppm was selected for selective irradiation in STD-NMR (saturation transfer difference) 294 experiments (weaker RBD signals below 0 ppm were also tested, and gave observable, but 295 weaker responses)¹³⁻¹⁶. For STD we used manufacturers 'stddiffgp19.3' pulse sequence with

296 watergate water suppression¹⁷. Selective saturation was achieved using a series of 50 ms 297 selective 90 degree Gaussian pulses, resulting in 2000 ms total irradiation time. The reference 298 experiment was carried out identically, except that an off resonance irradiation at -40 ppm was 299 applied. A total of 12160 scans interrupted with 2s relaxation delays were coadded in both the 300 on-resonance and the off-resonance (reference) experiments yielding one day total experiment 301 time. In the difference spectrum of the two experiments (FigS1H) the irradiated broad RBD 302 signal is the strongest among protein signals, while the six protons of rucaparib ligand-probably 303 closest to the binding site- gave the strongest responses. In the control experiment with no 304 RBD protein, the Rucaparib did not show the characteristic difference signals. An independent 305 corroboration of Rucaparib binding to RBD was carried out with the (non-selective) transferred 306 NOESY¹⁸ experiment ('noesygpph19' pulse sequence). Again, the fingerprint signals gave 307 cross-peaks with the same sign relative to the diagonal in the 2D NOESY map while they were 308 missing in a sample without the protein.

309

310 Transcription factor activation assay

Human peripheral blood mononuclear cells were differentiated to macrophages as described above. Cells were induced with the spike protein of SARS-CoV-2 (20 nM, 24 hours) and were treated with rucaparib in the concentrations indicated. Cell were then scraped whole cell lysates were used to perform transcription factor binding assays using TransAm kits (ActiveMotif Tegernheim, Bayern, Germany) similar to¹⁹. Stat family (Cat. No. 42296) was used in the study.

317

318 Statistical analyses

All experiments were repeated on at least three separate occasions, often with multiple parallel replicates processed on the same day, but treated as independently as possible. All graphs and statistical analyses were generated using GraphPad Prism v.8.0.1 software.

Numerical values are presented as the average \pm SD. Normality was checked. . *, **, *** represent statistically significant differences between the controls/vehicle-treated cells and patients/treated cells at p<0.05, p<0.01 and p<0.001, respectively.

325 Two-tailed Student's t-test on Figure 1 panel C and D

- 326 One-way ANOVA was used on Figure 1 panel B, Supplementary Figure 1 panels A, C, E and
- 327 F, in the post-hoc test all treatments were compared to the control.
- 328 One-way ANOVA was used on Figure 2 E and F and throughout Supplementary Figure 2,
- followed by a post-hoc test comparing all samples to the LPS or spike-treated groups.
- 330
- 331
- 332

333 Captions to supplementary Figures

Supplementary Figure 1. Olaparib and talazoparib do not block SARS-CoV-2 infection and rucaparib does not inhibit the macrodomain of SARS-CoV-2

336 (A) The antiproliferative and toxic effects of olaparib and talazoparib were tested in Vero E6 337 cells infected with of B.1.5 variant SARS-CoV-2. (B) Predicted binding mode of rucaparib 338 (green) at the protein-protein binding surface of the SARS-CoV2 RBD (fawn), overlaid on the 339 position of the ACE2 receptor (transparent blue). (C-F) A549 cells, either transduced with empty vector control (e.v.) or lentiviral constructs for FLAG-tagged SARS-CoV-2 macrodomain 340 341 overexpression (MD) were treated with either vehicle or different combinations of 100U IFNy, 342 500 nM or 20 µM rucaparib for 24 hours, as shown. ADP-ribosylation was detected by 343 immunofluorescence (C) and STAT1 phosphorylation, FLAG or tubulin levels were determined 344 by immunoblotting (D-F). All values were normalized to the IFNy-treated e.v. control. (G) 345 Excitation sculpting water suppression ¹H-NMR spectra using the manufacturer's 'zgesfpgp' 346 pulse sequence. Blue: no RBD, red: with RBD. (H) Whole difference spectrum of the Rucaparib 347 alone (blue), Rucaparib with RBD (green) and buffer alone (red). The red rectangle marks the 348 region displayed on Fig.2B.

349

Supplementary Figure 2. Rucaparib inhibits the LPS-induced overexpression of IL-8 and IL-10

352 (A) Human primary monocyte-derived macrophages were challenged with LPS (100 ng/mL,

353 24 hours) and indicated interleukins were determined. Three individual donors are displayed.

354 **(B)** A549 cells were induced with poly(I:C) and STAT1 phosphorylation was determined as 355 described in Materials and Methods. **(C)** Stat1, 3, 5A and 5B activation was determined in 356 human macrophages using the TransAM kit as described in the Materials and methods. One 357 donor is displayed.

Supplementary Table 1. Patient characteristics

For comparing age, normality was checked and two-sided, non-paired t-test was applied. AVG – average, CVE – cardiovascular event, DCM – dilated cardiomyopathy, F – female, IHD – ischaemic heart disease, GERD - Gastroesophageal reflux disease, M – male, n.s. – not significant

	Cont	trol p	atients	COVID-19 patients				
Patie identi	ent fier S	ex	Age	Patient identifier	Sex	Age		
1	F		66-70	1	М	56-60		
2 F			86-90	2	F	86-90		
3	F		81-85	3	F	81-85		
4	М		86-90	4	F	61-65		
5	М		66-70	5	F	81-85		
6	F		86-90	6	М	56-60		
7	М		56-60	7	М	61-65		
8	F		76-80	8	F	56-60		
9	М		81-85	9	F	76-80		
10	М		65-70	10	М	61-65		
				11	Μ	61-65		
				12	Μ	76-80		
				13	F	71-75		
				14	М	61-65		
				15	Μ	61-65		
10 patien	50% ts 50%	% M % F	77.1 ± 10.5 yrs	15 patients	53,3% M 46,7% F	69 ± 10.9 yrs ^{ns}		

Supplementary Table 2. Conditions for immunohistochemistry

Abbreviation: CC1 - ULTRA Cell Conditioning Solution (Ventana Medical Systems, Oro Valley, AZ, USA)

Primary Antibody						n retrieval: HER	Immunohistochemical stainers			
Antibody name	Vendor	Host	Dilution factor	Incubation time/temp.	Method	Time/Temp.	Visualization system	Enhancement	Counterstain	Staining Platform
Anti-4 Hydroxynonenal antibody (ab46545)	Abcam	rabbit polyclonal	1/400	32'/37 °C	CC1, pH8,5	36' ',95°C;	UltraView Universal DAB Detection Kit	CuSO4	Hematoxylin II	VENTANA BenchMark ULTRA
Poly(ADP-ribose) monoclonal antibody (10H). (ALX-804-220- R100)	Enzo	mouse monoclonal	1/2000	32'/37 °C		64 ',95°C;				
SARS-CoV-2 spike Glycoprotein S1 ab/ (ab275759)	Abcam	rabbit polyclonal	1/1000	1h /37 °C		56 ',100°C;				

References

- 1. Csonka, T., et al. Folia Neuropathologica 54, 114-126 (2016).
- 2. Kovács, P., et al. Cancers (Basel) 11, 1255 (2019).
- 3. Russo, L.C., et al. Journal of Biological Chemistry **297**, 101041 (2021).
- 4. Mahdi, M., Szojka, Z., Mótyán, J.A. & Tőzsér, J. *Journal of virology* **92**(2018).
- 5. Kozakov, D., *et al. Nat Protoc* **10**, 733-755 (2015).
- 6. Brenke, R., et al. Bioinformatics 25, 621-627 (2009).
- 7. Lan, J., *et al. Nature* **581**, 215-220 (2020).
- 8. Han, P., et al. Cell 185, 630-640.e610 (2022).
- 9. Sastry, G.M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. *Journal of computer-aided molecular design* **27**, 221-234 (2013).
- 10. Friesner, R.A., *et al. J Med Chem* **47**, 1739-1749 (2004).
- 11. Halgren, T.A., et al. J Med Chem 47, 1750-1759 (2004).
- 12. Hwang, T.L. & Shaka, A.J. *Journal of Magnetic Resonance, Series A* **112**, 275-279 (1995).
- 13. Mayer, M. & Meyer, B. Journal of the American Chemical Society **123**, 6108-6117 (2001).
- 14. Kövér, K.E., Groves, P., Jiménez-Barbero, J. & Batta, G. *J Am Chem Soc* **129**, 11579-11582 (2007).
- 15. Viegas, A., Manso, J., Nobrega, F.L. & Cabrita, E.J. *Journal of Chemical Education* **88**, 990-994 (2011).
- 16. Unione, L., et al. Angewandte Chemie International Edition 61, e202201432 (2022).
- 17. Piotto, M., Saudek, V. & Sklenář, V. Journal of Biomolecular NMR 2, 661-665 (1992).
- 18. Meyer, B., Weimar, T. & Peters, T. *Eur J Biochem* **246**, 705-709 (1997).
- 19. Brunyanszki, A., et al. Journal of Investigative Dermatology **130**, 2629-2637 (2010).